1. Home
  2. RGLS vs SKYX Comparison

RGLS vs SKYX Comparison

Compare RGLS & SKYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • SKYX
  • Stock Information
  • Founded
  • RGLS 2007
  • SKYX 2004
  • Country
  • RGLS United States
  • SKYX United States
  • Employees
  • RGLS N/A
  • SKYX N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • SKYX Building Products
  • Sector
  • RGLS Health Care
  • SKYX Consumer Discretionary
  • Exchange
  • RGLS Nasdaq
  • SKYX Nasdaq
  • Market Cap
  • RGLS 102.8M
  • SKYX 93.9M
  • IPO Year
  • RGLS 2012
  • SKYX 2022
  • Fundamental
  • Price
  • RGLS $1.46
  • SKYX $0.84
  • Analyst Decision
  • RGLS Strong Buy
  • SKYX Strong Buy
  • Analyst Count
  • RGLS 6
  • SKYX 2
  • Target Price
  • RGLS $10.33
  • SKYX $5.00
  • AVG Volume (30 Days)
  • RGLS 306.9K
  • SKYX 166.9K
  • Earning Date
  • RGLS 08-08-2024
  • SKYX 08-12-2024
  • Dividend Yield
  • RGLS N/A
  • SKYX N/A
  • EPS Growth
  • RGLS N/A
  • SKYX N/A
  • EPS
  • RGLS N/A
  • SKYX N/A
  • Revenue
  • RGLS N/A
  • SKYX $84,215,651.00
  • Revenue This Year
  • RGLS N/A
  • SKYX $55.89
  • Revenue Next Year
  • RGLS N/A
  • SKYX $44.10
  • P/E Ratio
  • RGLS N/A
  • SKYX N/A
  • Revenue Growth
  • RGLS N/A
  • SKYX 461.00
  • 52 Week Low
  • RGLS $1.08
  • SKYX $0.72
  • 52 Week High
  • RGLS $3.79
  • SKYX $1.95
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 37.78
  • SKYX 40.95
  • Support Level
  • RGLS $1.50
  • SKYX $0.80
  • Resistance Level
  • RGLS $1.72
  • SKYX $0.89
  • Average True Range (ATR)
  • RGLS 0.13
  • SKYX 0.06
  • MACD
  • RGLS -0.01
  • SKYX -0.01
  • Stochastic Oscillator
  • RGLS 14.29
  • SKYX 17.80

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About SKYX SKYX Platforms Corp.

SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. The company's technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post and is capable of feeding electric power to an appliance. The Company generates its income from the United States.

Share on Social Networks: